{"schema_version":"secwatch.filing_event.v1","accession":"0001837607-24-000092","form_type":"8-K","ticker":"AEON","cik":"0001837607","company_name":"AEON Biopharma, Inc.","filed_at":"2024-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.946414+00:00","generated_at":"2026-05-30T01:04:29.335067+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"medium","headline":"AEON Biopharma Q3 2024: FDA aligned on biosimilar path for ABP-450, but capital constraints persist","bullets":["Held Biosimilar Initial Advisory meeting with FDA in Q3; aligned on 351(k) pathway using BOTOX as reference.","Primary comparative analytical studies planned for Q4 2024, subject to securing capital resources.","BPD Type 2 meeting with FDA targeted in 2025 to discuss study outcomes.","CEO cites capital resources as single biggest limitation; evaluating all options to fund regulatory strategy."],"urls":{"canonical":"https://secwatch.observer/filing/0001837607-24-000092","json":"https://secwatch.observer/filing/0001837607-24-000092.json","markdown":"https://secwatch.observer/filing/0001837607-24-000092.md","text":"https://secwatch.observer/filing/0001837607-24-000092.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1837607/000183760724000092/0001837607-24-000092-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1837607/000183760724000092/aeon-20241113x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T01:04:29.335067+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}